Nasdaq · Industrials
Nutex Health Inc. (NUTX)
As-reported financials and recent SEC filings for Nutex Health Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$875.3M
Net income
$70.8M
Net margin
8.1%
Diluted EPS
$10.48
ROE
16.7%
P/E (TTM)
12.2×
Market cap
$1.15B
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $875.3M | $479.9M | $247.6M | $219.3M | $331.5M |
| Gross profit | — | — | — | — | — |
| Operating income | $275.6M | $130.7M | $-31.8M | $-406.6M | $170.3M |
| Net income | $70.8M | $52.1M | $-45.8M | $-424.8M | $132.6M |
| Diluted EPS | $10.48 | $9.69 | $-10.39 | $-100.36 | $30.80 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-04
View on EDGAR →42026-05-29
View on EDGAR →SCHEDULE 13G/A2026-05-07
View on EDGAR →8-K2026-04-30
View on EDGAR →10-Q2026-04-30
View on EDGAR →SCHEDULE 13G2026-04-27
View on EDGAR →42026-04-24
View on EDGAR →42026-04-24
View on EDGAR →Go deeper on NUTX
Search Nutex Health Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.